Study of Cosibelimab in Subjects With Relapsed or Refractory Lymphoma

• Status: Recruiting
• Trial end date: 2024-08-01
• Target enrollment: 0
• Participant gender: All

Summary

Phase 1 open label, multi-center, dose-escalation study for individuals with relapsed or refractory B-cell Non Hodgkin's Lymphoma.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: TG Therapeutics, Inc.
• Treatments: Antibodies, Monoclonal; Bendamustine Hydrochloride

Criteria

Key Inclusion Criteria:

• Histologically confirmed relapsed or refractory B-cell non-Hodgkin lymphoma (NHL).

• Measurable disease and adequate organ function as specified in the protocol

Key Exclusion Criteria:

• Prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, or prior therapy with bendamustine.

• Subjects receiving cancer therapy or investigational drug within 21 days of Cycle 1 Day 1.

• Prior autologous stem cell transplant within 3 months

• Active Hepatitis B or Hepatitis C